Therapeutic focus - Pfizer data highlights potential of JAKs in arthritis

Date November 11, 2010

Just like the oral revolution heading towards the multiple sclerosis market, data from Pfizer yesterday on tasocitinib suggests a similar transformation is possible in rheumatoid arthritis.

Encouraging pivotal data revealed at the ACR rheumatology conference confirms the pill, a JAK-3 inhibitor, is looking as effective and safe as the widely used injectable therapies available such as Humira, Enbrel and Remicade. These three products are expected to generate sales of $13bn in RA this year (see table below); although tasocitinib still has much to prove the potential is clear. As the analysis below shows the Pfizer product is by far the most advanced drug of its class, although several other JAK inhibitors are coming through, most notably a mid-stage candidate from Eli Lilly which also reported promising data at ACR.

This content is written, edited and published by EP Vantage and is distributed by Evaluate Ltd. All queries regarding the content should be directed to: news@epvantage.com

EP Vantage is a unique, forward-looking, news analysis service tailored to the needs of pharma and finance professionals. EP Vantage focuses on the events that will define the future of companies, products and therapy areas, with detailed financial analysis of events in real-time, including regulatory decisions, product approvals, licensing deals, patent decisions, M&A.

Drawing on Evaluate, an industry-leading database of actual and forecast product sales and financials, EP Vantage gives readers the insight to make value-enhancing decisions.

EP Vantage SM ©2018 EP Vantage Ltd